Augnition Labs was launched in 2020 with the mission of developing AI-powered digital assessment and monitoring solutions for early detection of cognitive decline.

As the world’s population continues to age, the number of people living with dementia is expected to rise to more than 153 million by 2050.

Alzheimer's disease is the most common type of dementia. It is a progressive neurological illness, beginning with memory loss and leading to compromised thinking, language and decision making.

Memory Loss comes first.

As the search continues for successful therapies that treat or prevent Alzheimer’s disease, one thing is certain – sensitive detection of the disease’s earliest symptoms is key to effective intervention.

Augmem™ is an innovative, AI-powered digital cognitive assessment tool that enables rapid, reliable and objective detection of memory loss years in advance. Read more about the science.

Why Does Augmem™ Matter to Clinical Trials and Research?

Augmem™ provides precise and accurate tracking of memory performance. Our leading technology is a world leader in screening, stratification, monitoring, and evaluation of treatment response.

Why Does Augmem™ Matter to Healthcare Professionals?

Augmem™ detects subtle shifts in memory, before the onset of clinical symptoms. Our precision tools enable earlier detection, leading to better outcomes, lower costs and prolonged quality of life. ​

Marco Peters, Ph.D.

Co-Founder and Scientific Advisor

Dr. Peters has over 20 years of experience in translational research, target discovery, and small molecule discovery for CNS indications. He built and managed small and large research teams, and his work has contributed to the discovery, progression, and clinical development of small molecule therapeutics for the treatment of multiple neurological indications including stroke, Alzheimer’s Disease, Parkinson’s disease, pain, and schizophrenia. He currently serves as vice president and head of translational science at Longboard Pharmaceuticals. Peters built the departments of Neurobiology and Behavioral Pharmacology, and managed target identification, in vivo pharmacology, and lead optimization at Dart Neuroscience. His work contributed to the advancement of multiple compounds into clinical development, and led to a broad intellectual property portfolio focused on enhancement of brain plasticity and cognitive function. Peters has a M.Sc. in Biochemistry from the Freie Universität Berlin, Germany and a PhD in Neuroscience from the University of London, UK. He conducted postdoctoral work on Alzheimer’s disease with Tetsuyuki Maruyama at Merck Sharp & Dohme (UK).